medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2020, Number 2

<< Back Next >>

Rev Latin Infect Pediatr 2020; 33 (2)

Tuberculosis in Latin America and its Impact on Pediatrics

Camacho-Badilla K, Camilo-de AE, Martínez CC, Castillo-Bejarano JI, Mascareñas-De SAH, López-López P

Language: Spanish
References: 46
Page: 66-73
PDF size: 199.67 Kb.


ABSTRACT

During 2018, 1.45 million deaths from tuberculosis (TB) were registered, this place TB as the main cause of death by a single microorganism, above HIV. Diagnostic-therapeutic approach represent a challenge for the clinician, the aim of this review is to document the most relevant aspects of the tuberculosis panorama in children.


REFERENCES

  1. World Health Organization. Global Tuberculosis Report 2019. Geneva, Switzerland: World Health Organization; 2019.

  2. World Health Organization. Tuberculosis. Disponible en: http://www.who.int/mediacentre/factsheets/fs104/en/.

  3. World Health Organization. Global Tuberculosis Report 2016. Disponible en: http://www.who.int/tb/publications/ global_report/en/.

  4. Seddon JA, Jenkins HE, Liu L, Cohen T, Black RE, Vos T et al. Counting children with tuberculosis: why numbers matter. Int J Tuberc Lung Dis. 2015; 19 Suppl 1 (0 1): 9-16.

  5. Comité Nacional de Neumonología; Comité Nacional de Infectología. Criterios de diagnóstico y tratamiento de la tuberculosis infantil. Resumen ejecutivo. Arch Argent Pediatr. 2016; 114 (2): 189-190.

  6. Mohapatra PR, Janmeja AK. Tuberculous lymphadenitis. J Assoc Physicians India. 2009; 57: 585-590.

  7. Sousa GJB , Silva JCO, Queiroz TV, Bravo LG, Brito GCB, Pereira AS et al. Clinical and epidemiological features of tuberculosis in children and adolescents. Rev Bras Enferm. 2019; 72 (5): 1271-1278.

  8. Neyro SE , Squassi IR, Medín M, Caratozzolo A, Martínez BA, Cerqueiro MC. Tuberculosis ganglionar periférica en pediatría: 16 años de experiencia en un centro pediátrico de tercer nivel de Buenos Aires, Argentina. Arch Argent Pediatr. 2018; 116 (6): 430-436.

  9. Carreto-Binaghi L , Juárez E, Guzmán-Beltrán S, Herrera M, Torres M, Sarabia C et al. Diagnosis of childhood tuberculosis at INER in 2015-2017. Neumol Cir Torax. 2018; 77 (4): 258-266.

  10. Martínez de Cuellar C , Lovera D, Gatti L, Ojeda L, Apodaca S, Zarate C et al. Tuberculosis: Factores de riesgo asociados a mortalidad en pacientes ≤ 19 años hospitalizados en el Instituto de Medicina Tropical. Pediatr (Asunción). 2019; 46 (2): 77-81.

  11. Zabaleta A , Llerena C, Valbuena A. Vigilancia por el laboratorio de la tuberculosis resistente en menores de 15 años, Colombia, 2010 a 2015. Biomédica. 2019; 39 (2): 330- 338.

  12. Vázquez RJ , Acosta GC, Miranda NM, Fuentes PY, Labra ZM, Pacheco RD, Solórzano SF. A case-series analysis of tuberculosis in pediatric patients treated in a tertiary level hospital. Bol Med Hosp Infant Mex. 2017; 74 (1): 27-33.

  13. Sreeramareddy CT, Panduru KV, Verma SC, Joshi HS, Bates MN. Comparison of pulmonary and extrapulmonary tuberculosis in Nepal-a hospital-based retrospective study. BMC Infect Dis. 2008; 8: 8.

  14. Marais BJ, Graham SN, Cotton MF, Beyers N. Diagnostic and management challenges for childhood tuberculosis in the era of HIV. J Infect Dis. 2007; 196 Suppl 1: S76-85.

  15. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017; 17 (2): 223-234.

  16. Atehortúa MS , Rendón MJ, Cárdenas MS, Arango FC, Cornejo OJ. Xpert MTB/RIF(r) as a diagnostic tool in a cohort of children under 15 years of age with clinical suspicion of pulmonary tuberculosis in a hospital of high complexity in Medellin. Infect. 2017; 21 (1): 25-31.

  17. De Sousa VP , Barbosa CS, Bierrenbach A, Basta P. Tuberculosis entre niños y adolescentes indígenas en Brasil: factores asociados al óbito y al abandono del tratamiento. Cad. Saúde Pública. 2019; 35 (Suppl. 3): e00074218.

  18. Stagg HR, Harris RJ, Hatherell HA, Obach D, Zhao H, Tsuchiya N et al. What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax. 2016; 71 (10): 940-949.

  19. Ramos AJ. Actualización en tuberculosis infantil. EEPap. 2018; 2253-2257.

  20. Farga V, Caminero J. Tuberculosis. 3ra ed. Santiago de Chile: Mediterráneo; 2011.

  21. Guarda ME . Tuberculosis en el niño ¿Cómo se diagnostica? Revista Médica Clínica Las Condes. 2017; 28 (1): 104-110.

  22. Arias M, Herrera T. Nuevos métodos para el diagnóstico de la tuberculosis. Rev Chil enferm resp. 2016; 32 (4): 254-259.

  23. Herrera FA . Nuevos métodos para el diagnóstico de la tuberculosis. Rev Chil Enferm Respir. 2016; 32: 254-259.

  24. OPS. Rapid Communication: Molecular assays as initial tests for the diagnosis of tuberculosis and rifampicin result. Washington: OPS, 2020.

  25. World Health Organization. Global tuberculosis report. World Health Organization, Geneva, Switzerland. 2017. Available at: http://www.who.int/tb/publications/global_report/en/.

  26. Marais BJ , Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004; 8 (4): 392-402.

  27. Khan A, Sterling TR, Reves R, Vernon A, Horsburgh CR. Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med. 2006; 174: 344-348.

  28. World Health Organization. Rapid advice: treatment of tuber- culosis in children. Geneva: WHO; 2010.

  29. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2nd ed. Geneva, Switzerland: WHO; 2014.

  30. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet. 2005; 365: 130-134.

  31. Santos G, Oliveira O, Gaio R, Duarte R. Effect of isoniazid resistance on the tuberculosis treatment outcome. Arch Bron Coneumol. 2017. pii: S0300-2896(17)30215-6.

  32. American Academy of Pediatrics, Committee on Infectious Dis- eases. 2015 Red Book: Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: AAP; 2015.

  33. Cruz AT, Starke JR. Twice-weekly therapy for children with tuberculosis infection or exposure. Int J Tuberc Lung Dis. 2013; 17: 169-174.

  34. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR. Predictors of failure to complete therapy for latent tuberculosis infection. J Infect. 2007; 54 (3): 262-266.

  35. Kwara A, Herold JS, Machan JT, Carter EJ. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest. 2008; 133 (4): 862-868.

  36. Harausz EP , Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon J et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018; 15 (7): e1002591.

  37. The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Management of multidrug-resistant tuberculosis in children: a field guide: Boston, USA; 2019 [Access Year |;Access Date; 2019; 10 April]. Fourth: [Available from: http://sentinel-project.org/wp-content/uploads/2019/02/Updated_DRTB-Field-Guide-2019-V3.pdf.

  38. O’Brien RJ, Long MW, Cross FS, Lyle MA, Snider DE. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics. 1983; 72 (4): 491-499.

  39. Palusci VJ, O’Hare D, Lawrence RM. Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. Pediatr Infect Dis J. 1995; 14: 144-148.

  40. Biehl JP, Vilter RW. Effects of isoniazid on pyridoxine metabolism. JAMA. 1954; 156: 1549-1552.

  41. Biehl JP, Vilter RW. Effect on isoniazid on vitamin B6 metabolism: its possible significance in producing isoniazid neuropathy. Proc Soc Biol Med. 1954; 85: 389-392.

  42. Pellock JM , Howell J, Kendig EL Jr, Baker H. Pyridoxine deficiency in children treated with isoniazid. Chest. 1985; 87 (5): 658-661.

  43. Morales SM, Lincoln EM. The effect of isoniazid therapy on pyridoxine. Rev Tuberc. 1957; 75: 594-600.

  44. Cillers K, Labadarios D, Schaaf HS et al. Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid. Acta Paediatr. 2010; 99: 705-710.

  45. Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005; 90 (6): 614-618.

  46. Minns AB, Ghafouri N, Clark RF. Isoniazid induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy. Pediatr Emerg Care. 2010; 26 (5): 380-381.




2020     |     www.medigraphic.com